18 August 2020>: Clinical Research
Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
Ling Zhu 12ABCDEFG , Qianwei Cui 1BCEF , Ying Liu 3BCEF , Zhongwei Liu 1BCE , Yong Zhang 1BCF , Fuqiang Liu 1ACDEFG* , Junkui Wang 1ACDEFG*DOI: 10.12659/MSM.925114
Med Sci Monit 2020; 26:e925114
Figure 1 The cumulative incidence of major adverse cardiovascular events (MACEs). Compared with no therapy group, the cumulative incidence of MACEs gradually decreased in the beta-blocker monotherapy group, statin monotherapy group, and cotherapy group (P<.001).